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Cefuroxime Pharmacokinetics in Pediatric Cardiovascular Surgery Patients Undergoing
Cardiopulmonary Bypass
C A Knoderer; S A Saft; S G Walker; M D Rodefeld; M W Turrentine; J W Brown; D P
Healy; K M Sowinski
Objectives
The objective of this study was to determine the pharmacokinetics of cefuroxime in children undergoing
cardiopulmonary bypass (CPB) for cardiovascular surgery.
Design
A prospective study.
Setting
A tertiary pediatric teaching hospital.
Participants
Infants and children undergoing CPB were enrolled in the study.
Intervention
An initial dose (mean, 24.2 ± 1.6 mg/kg) of cefuroxime was administered before surgical incision, and a
second dose (mean, 14.4 ± 7.9 mg/kg) was administered in the CPB prime solution. Serial blood samples
were obtained before, during, and after the CPB process. Samples were shipped on dry ice to the analytic
laboratory and concentrations determined by a validated high-performance liquid chromatography
method. A 2-compartment pharmacokinetic model was fitted to the data using maximum a priori–
Bayesian estimation, with weight as a covariate. Monte Carlo simulations of a single-dose (25 mg/kg preCPB) approach and a 2-dose (25 mg/kg pre- and 12.5-mg/kg prime solution dose) approach were
performed.
Measurements and Main Results
Fifteen subjects (9 males/6 females) were enrolled in the study, with median (range) age and weight of 11
(3-34) months and 9.5 (4.5-15.4) kg, respectively. The median (range) duration of CPB was 136 (71-243)
minutes. Median and range cefuroxime pharmacokinetic parameters were as follows: maximum
concentration (Cmax) dose, 1: 328 (150-512) μg/mL; systemic clearance, 0.050 (0.041-0.058) L/h/kg;
steady-state volume of distribution, 0.213 (0.081-0.423) L/kg; volume of distribution in the central
compartment, 0.081 (0.046-0.162) L/kg; and elimination half-life, 3.76 (1.03-6.81) hours. The median 8hour post–dose-simulated cefuroxime concentrations were 26.5 and 16.0 mg/L for the 2-dose and singledose regimens, respectively.

Conclusion
Manufacturers recommend that pediatric doses of cefuroxime (25-50 mg/kg) can be used in infants and
children undergoing CPB to maintain adequate serum concentrations for surgical-site infection
prophylaxis. A second intraoperative dose, administered through the CPB circuit, provides no additional
prophylactic advantage.

Surgical-site infections (SSIs) account for approximately 16% of hospital-acquired infections. 1
Of particular concern for patients undergoing cardiac surgery are deep sternal wound infections
or mediastinitis after procedures with a median sternotomy. Sternal wound infections occur in
5% of all children after median sternotomy. 2 Associated mortality is significant and has been
reported to be as high as 60% in adults although there are little comparable data for children. 3
Estimates of sternal wound infections in pediatric patients after cardiac surgery vary from 3% for
superficial sternal infections, 2% for deep sternal infections, to 0.04% to 3.9% for mediastinitis. 2
456
Incidence of sternal wound infection has been shown to be greater in neonates (5.5%) versus
older children (0.5%), and was associated with increased morbidity and mortality in the neonatal
group. 7
Incisional cellulitis and fever are common presenting signs of sternal wound infection in
children. This likely is secondary to interruption of the skin barrier and further complicated by
the placement of percutaneous devices that then may be colonized and potentially infected along
the tract. In multiple series, staphylococcal species ( Staphylococcus aureus and Staphylococcus
epidermidis ) were the most common infecting pathogens. 2 3 8 9 10 For antimicrobial prophylaxis
for cardiac surgery, a cephalosporin, such as cefazolin or cefuroxime, is the preferred agent
unless a high probability of methicillin-resistant S aureus (MRSA) is suspected or the patient has
a β-lactam allergy. 11 The minimum inhibitory concentration (MIC) value for staphylococcal
species susceptible to parenteral cefuroxime is ≤8 μg/mL. 12
A review of the literature shows limited pediatric data describing cardiopulmonary bypass (CPB)
effects on prophylactic antibiotic therapy; none of which describes cefuroxime. 13 14 Children
may have a greater hemodilution effect from CPB initiation than adults, and extrapolating from
adult cefuroxime data creates inaccuracy. 15 Definitive recommendations for redosing of
intraoperative antibiotic prophylaxis because of CPB effects are not available for children
undergoing surgery for congenital heart defects. To adequately prevent SSI and subsequent
morbidity and mortality, an additional intraoperative cefuroxime dose could be required if the
cefuroxime serum concentration falls to below desired concentrations. The objective of this
study was to determine the pharmacokinetics of cefuroxime in pediatric patients undergoing
cardiac surgery with CPB. The authors also sought to evaluate whether doses currently used
achieved appropriate concentrations for protection against potential pathogens.

Methods
Fifteen children between 1 month and 3 years of age who required CPB for their surgical repair
were included. Subjects were excluded if they had an allergy to β-lactam antibiotics; were born
at less than 36 weeks' gestational age or were older than 3 years (3 years and 0 days); had an
anticipated CPB time of less than 30 minutes; or had a history of culture positive for MRSA,
ventricular-assist device therapy, or cardiac transplantation. This study was conducted after

approval from the institutional review board at Indiana University-Purdue University,
Indianapolis, IN. Informed consent for the study was obtained from the parent or guardian at the
time of surgical consent.
Demographic data collected on all patients included sex, age, weight, serum creatinine, cardiac
defect, and repair. Temperature, perfusion priming volume, time on CPB, coldest temperature,
and modified ultrafiltration volume were collected from perfusion and anesthesia records. The
contents of the CPB prime solution could vary per patient and contain, but were not limited to,
plasmalyte, albumin, methylprednisolone, sodium bicarbonate, blood, and cefuroxime.
Cefuroxime (target dose, 25 mg/kg) was administered through an intravenous catheter within 1
hour before skin incision. A second dose of cefuroxime (target dose, 12.5 mg/kg) was
administered in the CPB prime solution. Both doses were administered according to institutional
standard. Seven serial blood samples were obtained before, during, and after CPB at the time
points described in Table 1 . The times at which these samples were taken were targeted at the
times described although the actual times varied depending on the clinical situation. The first
sample was obtained by using excess blood from the routine baseline preoperative laboratory
samples. The other blood samples (5 mL each) were obtained via arterial hemodynamic
catheters, which all patients receive as a standard of cardiovascular surgical care, or directly from
the CPB circuit (considered postcircuit). Blood samples were obtained by either the
anesthesiologist or perfusionist while the patient remained in the operating room and by a
pediatric intensive care unit nurse after surgery. Blood samples were collected into heparinizedevacuated blood-collection tubes. Samples were mixed and centrifuged, and the plasma was
collected and stored frozen at −70°C. Samples were shipped on dry ice to the analytic laboratory
for analysis and processed within 4 weeks of receipt.
Table 1
Timing of Blood Samples for the Determination of Cefuroxime Pharmacokinetics
Sample
Intraoperative Event
Approximate Time Relation to Cefuroxime Dosing
1
Before cefuroxime dose
−12 to 72 hours
2
Heparin administration
+70 minutes
3
5 minutes after initiation of CPB
+90 minutes
4
Initiation of rewarming
+180 minutes
5
Separation from bypass
+210 minutes
6
5 minutes after protamine administration +230 minutes
7
Arrival in the intensive care unit
+260 to 290 minutes

Plasma concentrations of cefuroxime were determined by a modified reverse-phase highperformance liquid chromatography method with ultraviolet detection (214 nm) per previously
described techniques. 16 17 Samples were processed by protein precipitation with 4% perchloric
acid with tinidazole (10 μg/mL, Sigma, St. Louis, MO) used as the internal standard. Five
hundred microliters of solution were added to 250 μL of sample, standard, or spiked control. The
samples then were vortexed for 30 seconds followed by centrifugation at 3.0 g for 15 minutes. A
50-μL portion of supernatant was injected directly onto the high-performance liquid
chromatography column, and the peak-area ratio of cefuroxime-to-internal standard was
analyzed. The only modification to the analytic procedure was the use of 2 Onyx monolithic C18
analytic columns (50 × 4.6 mm) placed in series (Phenomenex, Torrance, CA). The range of

assay linearity was 5.0 to 200 μg/mL ( r ≥ 0.998, n = 7); specimens with concentrations >200
μg/mL were diluted with blank pooled human plasma and reassayed. The limit of assay detection
with a 50-μL injection volume was 1.0 μg/mL. The within-day (n = 5) and between-day (n = 7)
coefficients of variation for spiked control specimens (5, 50, and 200 μg/mL) were ≤3.4% and
≤8.2%, respectively.
Initial estimates of cefuroxime pharmacokinetics were determined by noncompartmental
techniques using the individual concentration-time data. After visualizing the concentration-time
profile and the 2-exponential decline characteristics, a 2-compartment model was chosen as the
structural pharmacokinetic model. Equations describing a 2-compartment, pharmacokinetic
model were fitted to each subject's cefuroxime concentration-time data using ADAPT 5 18 with
the weighted least-squares estimator. The pharmacokinetic parameters estimated were as
follows: Vc, the apparent volume of distribution in the central compartment; Vp, the apparent
volume of distribution in the peripheral compartment; Cld, the distribution clearance between the
central and peripheral compartment; and Cls, systemic clearance, which was assumed not to
change over the course of the entire study period. The weighting scheme used was 1/(observed
concentration) 2 . After completion of the initial weighted least-squares fitting process, the
impact of weight as a coavariate on pharmacokinetics was investigated. The authors observed a
significant relationship between weight and pharmacokinetic parameters. The same structural
model was fit to the data this time using the maximum a priori (MAP)-Bayesian estimator in
ADAPT 5. The initial pharmacokinetic parameter estimates with their associated intersubject
variability were used as initial MAP-Bayesian estimators, with Vc and Cls normalized for
subject weight. The variance model assumed the standard deviation of the residuals was linear
with increasing concentrations using the following equation: f(V) = [y int + m(y)] 2 , where y int is
the y-intercept of the residual plot and m is the slope of the line. The y-intercept was fixed at
one-half of the lower limit of detection for the cefuroxime assay. The slope (m) was estimated in
each individual subject. The same pimary pharmacokinetic parameters were estimated with this
model. The secondary parameters estimated in this model were apparent steady-state volume of
distribution (Vss), elimination rate constant, and elimination half-life (t1/2). Secondary
parameters were calculated by standard equations. Model fits were assessed by visual inspection
of the predicted versus measured data and the distribution of the weighted residuals.
One hundred simulations were performed using the MAP-Bayesian–generated pharmacokinetic
estimates using 2 dosing schemes: (1) an initial 25-mg/kg intravenous dose followed by a 12.5mg/kg prime dose (study dose), and (2) an initial 25-mg/kg intravenous dose. Each simulation
consisted of using the mean and variance of the pharmacokinetic parameters (Vc, Vp, Cls, and
Cld) from the final pharmacokinetic analysis as described previously, with the parameters listed
in Table 2 .

Table 2
Subject Demographics
Subject Sex RACHS
1

M 3

Minimal
Temperature
(°C)
28

Age
Dose 1
(Months) (mg/kg)
19

24.8

Dose 2
(mg/kg)
6.76

PrePostPrime
Height
Duration of
weight weight
Vol
(cm)
CPB (min)
(kg)
(kg)
(mL)
11.1
11.1
81
830
124

Minimal
Temperature
(°C)
2
28
3
27
3
26.6
3
28
3
30
2
26.1
4
25
4
28
3
28
3
30
4
26
3
27
3
26
3
29
Mean
27.5
SD
1.5
Median 28

Subject Sex RACHS
2
3
4
5
6
7
8
9
11
12
13
14
15
16

M
M
F
F
M
F
M
M
F
M
F
F
M
M

Age
Dose 1
(Months) (mg/kg)
17
4.5
11
18
27
9
9
10
23
11
12
6
3
33.6
14.2
8.65
11.0

24.3
23.2
26.7
22.1
25.4
23.8
24.2
23.6
27.0
25.6
23.3
23.7
20.9
24.4
24.2
1.59
24.2

Dose 2
(mg/kg)
14.6
12.5
None
11.5
12.3
11.9
12.1
28.3
12.6
12.6
29.1
27.0
11.5
12.7
14.4
7.94
12.5

Preweight
(kg)
10.3
5.3
7.9
10.6
13.6
8.4
8.7
10
10.2
7.8
9.5
7.1
4.5
15.4
9.36
2.83
9.50

Postweight
(kg)
10.3
5.4
9.0
11.3
13.8
8.4
9.1
10.6
10.2
7.8
10.3
7.4
4.8
15.4
9.66
2.80
10.2

Height
(cm)
71
65
72
85
92
76
67
76
81
74
74
66
62
94
75.7
9.51
74.0

Prime
Vol
(mL)
570
515
600
565
825
620
715
450
675
630
1000
650
670
770
672.3
139.7
650

Duration of
CPB (min)
125
168
165
151
75
163
405
93
154
124
107
108
120
93
145
77.5
124

Demographic study data were collected and reported by descriptive statistics. Regression
analysis was used to determine the relationship between weight and the initial pharmacokinetic
parameter fits. Statistical analysis was performed using Graph Pad Prism (v 5.2; Graph Pad
Software Inc., La Jolla, CA). Statistical significance was defined as a p value of <0.05.

Results
Sixteen subjects provided informed consent and were enrolled. Because of a protocol violation,
15 subjects (9 male subjects and 6 female subjects) completed the study. The subject
demographics are shown in Table 2 . As shown in Table 2 , all but 1 subject received 2 doses of
cefuroxime. No adverse effects were reported related to cefuroxime.
The mean cefuroxime pharmacokinetic parameters are shown in Table 3 . Individual cefuroxime
plasma concentration-time curves, both observed and modeled data, in 6 representative subjects
are shown in Figure 1 . As evidenced by this figure, there was good agreement between the fitted
and observed data. The simulated cefuroxime concentration-time curves for the 2 cefuroxime
dosing regimens are shown in Figure 2 . Median 8-hour postdose-simulated cefuroxime
concentrations were 26.5 and 16.0 mg/L for the 2-dose and single-dose regimens, respectively.

Fig 1
Representative individual observed and modeled cefuxoxime concentration-time curves in 6 subjects. Observed data are
indicated by the closed circles and modeled data by the solid lines. Subjects 3, 7, and 12 were younger than 1 year of age and
subjects 5, 13, and 16 were older than 1 year of age.

Fig 2

Simulated cefuroxime mean concentration-time profiles for 2 dosing regimens, a 25-mg/kg single dose (closed circles, solid line)
and a 25-mg/kg initial dose followed by 12.5 mg/kg dose in the CPB prime solution (open boxes, dotted line).
Table 3
Mean and Standard Deviation (SD) Cefuroxime Pharmacokinetic Parameters
Mean

SD

Cld (mL/min/kg)

43.9

40.2

Cls (mL/min/kg)

11.8

4.79

Vp (L/kg)

8.08

4.49

Vc (L/kg)

8.53

3.72

Vss (L/kg)

0.2104 0.0605

t½ (h)

19.1

β (h)

0.037 0.006

Cmax 1st dose (μg/mL) 328

3.51

102

Discussion
Cefuroxime is the preferred prophylactic antibiotic for pediatric cardiovascular surgery at the
authors' institution. The initial dose is administered within 60 minutes of incision, and, in
accordance with Surgical Infection Prevention (SIP) project and Society of Thoracic Surgeons
(STS) recommendations, redosing is considered for procedures past 4 hours in length, regardless
of the use of CPB. 11 19 However, there are no published data regarding cefuroxime
pharmacokinetics during pediatric cardiac surgeries requiring CPB and no pediatric-specific
recommendations for the redosing of cefuroxime in these procedures. Pharmacokinetic
differences observed in children when compared with adults make extrapolating adult literature
difficult. 20
CPB is a multiphased process with potential to alter the pharmacokinetic properties of a variety
of medications including antibiotics. 15 21 Prolonged CPB time has been linked to increased
infection risk, thus making optimization of antibiotic prophylaxis critical. 2 22 Caffarelli et al
showed inadequate cefazolin serum concentrations after single prophylactic cefazolin doses for
cardiac surgeries requiring longer than 120 minutes on CPB. 23 In the present study population,
the average time on CPB was 145 minutes, making this an important factor. CPB-related
hemodilution, as a result of the administration of blood and primer solution, decreases total
serum concentration of medications through altering the volume of distribution of drugs. 26 27
This effect has been shown with cephalosporins. 24 25 Cefazolin concentrations decrease 32% to
62% as a result of the hemodilution effects of CPB. 14 26

Multiple studies have investigated the pharmacokinetics of cefuroxime during CPB although
none has been performed in children, making comparison to the present results difficult. 16 27 28 29
However, it appears through the findings of Nascimento et al and Vuorisalo et al that cefuroxime
pharmacokinetics in adults undergoing CPB are not altered by CPB. 27 29 The present findings in
children are similar in that CPB does not appear to alter cefuroxime pharmacokinetics.
Alternative cefuroxime dosing regimens, such as continuous infusion cefuroxime, have been
studied in adults undergoing cardiac surgery, but making extrapolation to children is difficult
because of the differences in dosing. 16
Patients with congenital heart defects are a uniquely ill population with generally immature
immune systems. 7 Children less than 1 year of age are the largest group undergoing surgery for
congenital heart lesions. Fragility in the infant and postoperative period likely contribute to
making deep sternal wound infections a life-threatening complication in this population.
Additionally, infants requiring CPB may undergo deep hypothermic circulatory arrest resulting
in decreased immune function. 30 Blunting of the immune response also may occur secondary to
prolonged periods of diminished cardiac output. 31 Children with prolonged CPB time, long
aortic cross-clamp time, long total operation time, and high-body-mass index have an increased
risk for developing SSIs. 22 32 Optimizing the pharmacodynamic properties of perioperative
antibacterial regimens is imperative to prevent infection.
The only study to examine cephalosporin pharmacokinetics in children undergoing CPB used
cefazolin with gentamicin in infants less than 10 kg. 14 The investigators found that cefazolin
distribution volume and elimination are altered by CPB, but that their dosing regimen (35 mg/kg)
used, which is slightly higher than the recommended dosing range, remained effective for
optimal infection prevention. 1 33 Comparing the present findings with those of Haessler et al 14 is
difficult given the inherent differences in pharmacokinetic profiles between cefazolin and
cefuroxime. Cefazolin is much more highly protein bound than cefuroxime. 34 Hemodilutionrelated decreases in circulating plasma proteins, specifically albumin and α-acid glycoprotein,
may result in increased free drug and redistribution of drug to tissues as a result of CPB, and may
lead to an overall increased free fraction of cefazolin. 21 24 This may not be applicable to
cefuroxime given the minimal protein binding as compared with cefazolin.
In general, maximum bacterial killing for cephalosporins is observed when serum concentrations
(unbound drug) are maintained above the MIC for 60% to 70% of the dosing interval, although a
lower percentage may be required for staphylococcal species. 35 Cephalosporins, such as
cefuroxime, are preferred antimicrobials for prophylaxis after cardiac surgery, in part because of
the activity against S aureus and S epidermis . 11 The median 8-hour postdose-simulated
cefuroxime concentrations were 26.5 and 16.0 mg/L for the 2-dose and single-dose regimens,
respectively. Given the protein binding of cefuroxime of approximately 30%, either a 2-dose or
single-dose intraoperative regimen would result in a serum concentration above the MIC for
staphylococcal species for 100% of the dosing interval based on when the postoperative regimen
would be the initiated model. 34 It appears as though a second intraoperative dose, administered
through the CPB circuit, provides no additional prophylactic advantage. Currently, the
manufacturer's recommended pediatric doses of cefuroxime (25-50 mg/kg) can be used in infants
and children undergoing CPB to maintain adequate serum concentrations for SSI prophylaxis.
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